Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shihchen Kuo

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Endocrinology and Metabolism Clinics of North America|November 12, 2021
100 years of Insulin: Why is Insulin So Expensive and What Can be Done to Control Its Cost?William H Herman, Shihchen Kuo
Diabetes Care|June 12, 2025
Is Screening for Heart Failure and Peripheral Artery Disease Warranted in Asymptomatic Adults With Diabetes? A Perspective on the 2025 American Diabetes Association "Standards of Care in Diabetes"William H Herman, Shihchen Kuo
Diabetes, Obesity & Metabolism|December 18, 2024
A comment on "Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was"William H Herman, Shihchen Kuo, Ping Zhang, et al.
Journal of the American Pharmacists Association : Japha|September 13, 2020
Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the futureShihchen Kuo, Huang-Tz Ou, C Jason Wang
Gastroenterology|July 6, 2010
In a 12-year study, sustainability of quality of life benefits after liver transplantation varies with pretransplantation diagnosisKristine Ruppert, Shihchen Kuo, Andrea DiMartini, et al.
Diabetes Research and Clinical Practice|May 7, 2018
Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trialShihchen Kuo, Wen Ye, Justin Duong, et al.
Current Diabetes Reports|July 26, 2017
Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost?Laura N McEwen, Sarah Stark Casagrande, Shihchen Kuo, et al.
Journal of Diabetes Investigation|February 4, 2021
Valuing health states of people with type 2 diabetes: Analyses of the nationwide representative linked databasesShihchen Kuo, Chun-Ting Yang, Hsuan-Ying Chen, et al.
Diabetes, Obesity & Metabolism|April 4, 2022
Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: A model-based simulation analysis using 10-year real-world data and targeted literature reviewZi-Yang Peng, Chun-Ting Yang, Huang-Tz Ou, et al.
British Journal of Clinical Pharmacology|November 30, 2019
Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 yearsTsung-Ying Lee, Shihchen Kuo, Chen-Yi Yang, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Endocrinology and Metabolism Clinics of North America|November 12, 2021
100 years of Insulin: Why is Insulin So Expensive and What Can be Done to Control Its Cost?William H Herman, Shihchen Kuo
Diabetes Care|June 12, 2025
Is Screening for Heart Failure and Peripheral Artery Disease Warranted in Asymptomatic Adults With Diabetes? A Perspective on the 2025 American Diabetes Association "Standards of Care in Diabetes"William H Herman, Shihchen Kuo
Diabetes, Obesity & Metabolism|December 18, 2024
A comment on "Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never was"William H Herman, Shihchen Kuo, Ping Zhang, et al.
Journal of the American Pharmacists Association : Japha|September 13, 2020
Managing medication supply chains: Lessons learned from Taiwan during the COVID-19 pandemic and preparedness planning for the futureShihchen Kuo, Huang-Tz Ou, C Jason Wang
Gastroenterology|July 6, 2010
In a 12-year study, sustainability of quality of life benefits after liver transplantation varies with pretransplantation diagnosisKristine Ruppert, Shihchen Kuo, Andrea DiMartini, et al.
Diabetes Research and Clinical Practice|May 7, 2018
Are the favorable cardiovascular outcomes of empagliflozin treatment explained by its effects on multiple cardiometabolic risk factors? A simulation of the results of the EMPA-REG OUTCOME trialShihchen Kuo, Wen Ye, Justin Duong, et al.
Current Diabetes Reports|July 26, 2017
Why Are Diabetes Medications So Expensive and What Can Be Done to Control Their Cost?Laura N McEwen, Sarah Stark Casagrande, Shihchen Kuo, et al.
Journal of Diabetes Investigation|February 4, 2021
Valuing health states of people with type 2 diabetes: Analyses of the nationwide representative linked databasesShihchen Kuo, Chun-Ting Yang, Hsuan-Ying Chen, et al.
Diabetes, Obesity & Metabolism|April 4, 2022
Cost-effectiveness of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors among patients with type 2 diabetes with and without established cardiovascular diseases: A model-based simulation analysis using 10-year real-world data and targeted literature reviewZi-Yang Peng, Chun-Ting Yang, Huang-Tz Ou, et al.
British Journal of Clinical Pharmacology|November 30, 2019
Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 yearsTsung-Ying Lee, Shihchen Kuo, Chen-Yi Yang, et al.
Pageof 7